A61P 33/02
Antiprotozoals
Official title: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
A61P33/02 (Antiprotozoals) appears on 4,392 US grants and 6,236 published applications in this corpus.
Search patents in A61P- Granted patents
- 4,392
- Published applications
- 6,236
- Assignees
- 2,423
- Inventors
- 11,744
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 6 | 0 |
| 1978 | 6 | 0 |
| 1979 | 6 | 0 |
| 1980 | 9 | 0 |
| 1981 | 24 | 0 |
| 1982 | 9 | 0 |
| 1983 | 8 | 0 |
| 1984 | 7 | 0 |
| 1985 | 6 | 0 |
| 1986 | 8 | 0 |
| 1987 | 12 | 0 |
| 1988 | 8 | 0 |
| 1989 | 18 | 0 |
| 1990 | 26 | 0 |
| 1991 | 13 | 0 |
| 1992 | 18 | 0 |
| 1993 | 13 | 0 |
| 1994 | 19 | 0 |
| 1995 | 22 | 0 |
| 1996 | 25 | 0 |
| 1997 | 56 | 0 |
| 1998 | 62 | 0 |
| 1999 | 72 | 0 |
| 2000 | 68 | 0 |
| 2001 | 86 | 27 |
| 2002 | 108 | 117 |
| 2003 | 112 | 246 |
| 2004 | 67 | 307 |
| 2005 | 91 | 275 |
| 2006 | 115 | 280 |
| 2007 | 112 | 271 |
| 2008 | 124 | 293 |
| 2009 | 139 | 385 |
| 2010 | 204 | 518 |
| 2011 | 200 | 433 |
| 2012 | 275 | 443 |
| 2013 | 291 | 286 |
| 2014 | 307 | 302 |
| 2015 | 250 | 268 |
| 2016 | 234 | 250 |
| 2017 | 214 | 216 |
| 2018 | 165 | 217 |
| 2019 | 144 | 224 |
| 2020 | 149 | 175 |
| 2021 | 124 | 164 |
| 2022 | 90 | 159 |
| 2023 | 76 | 129 |
| 2024 | 77 | 106 |
| 2025 | 72 | 90 |
| 2026 | 40 | 55 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chagas disease vaccine antigens with improved stability and decreased aggregation29 Sep 2026US 12,746,280 B2Baylor College of Medicine
- Anticoccidial composition comprising violacein, and use thereof1 Sep 2026US 12,721,835 B2Cj Cheiljedang Corporation
- Immune priming to accelerate/enhance immune response through administration of natural immune modulator1 Sep 2026US 12,721,889 B2ZIVO Bioscience, Inc.
- Reducing malaria transmission25 Aug 2026US 12,714,109 B2GlaxoSmithKline Intellectual Property Development Limited
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- Crispr-cas genome engineering via a modular aav delivery system8 Oct 2026US 2026/0308630 A1The Regents of the University of California
- Biologically compatible, biofilm disrupting composition and methods1 Oct 2026US 2026/0294861 A1
- Liposomal formulation for treatment of visceral leishmaniasis24 Sep 2026US 2026/0284167 A1Council of Scientific and Industrial Research
- Feed additive for improving performance of farming animals17 Sep 2026US 2026/0273007 A1
- Live attenuated leishmania parasite vaccines with enhanced safety characteristics17 Sep 2026US 2026/0273036 A1Ohio State Innovation Foundation
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Process for preparing diaminophenothiazinium compounds687US 8,765,942 B2Provence Technologies · 2014
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003